Showing results (71-80 of 153) with videos related to
Sort By:
Pageof 16
JAMA Network Open|August 30, 2021
Racial/Ethnic Differences in COVID-19 Vaccine Hesitancy Among Health Care Workers in 2 Large Academic HospitalsFlorence M Momplaisir, Barbara J Kuter, Fatemeh Ghadimi, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|December 21, 2006
Incidence and risk factors for weight loss during dual HIV/hepatitis C virus therapyVincent Lo Re, Jay R Kostman, Robert Gross, et al.Health Promotion Practice|October 27, 2012
The development of a culturally relevant, theoretically driven HPV prevention intervention for urban adolescent females and their parents/guardiansBridgette M Brawner, Jillian L Baker, Chelsea D Voytek, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|December 13, 2006
Prevalence, risk factors, and outcomes for occult hepatitis B virus infection among HIV-infected patientsVincent Lo Re, Ian Frank, Robert Gross, et al.Journal of Immunology (Baltimore, Md. : 1950)|November 4, 2006
Preservation of T cell proliferation restricted by protective HLA alleles is critical for immune control of HIV-1 infectionHelen Horton, Ian Frank, Ruth Baydo, et al.AIDS Research and Human Retroviruses|December 16, 2004
Activity, safety, and immunological effects of hydroxyurea added to didanosine in antiretroviral-naive and experienced HIV type 1-infected subjects: a randomized, placebo-controlled trial, ACTG 307Ian Frank, Ronald J Bosch, Susan Fiscus, et al.Journal of Urban Health : Bulletin of the New York Academy of Medicine|March 7, 2015
HIV Sexual Risk and Syndemics among Women in Three Urban Areas in the United States: Analysis from HVTN 906Beryl A Koblin, Shannon Grant, Victoria Frye, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|November 7, 2018
Brief Report: Rate of Nicotine Metabolism and Tobacco Use Among Persons With HIV: Implications for Treatment and ResearchRobert A Schnoll, Morgan Thompson, Katrina Serrano, et al.AIDS and Behavior|July 27, 2017
Lessons for Patient Education Around Long-Acting Injectable PrEP: Findings from a Mixed-Method Study of Phase II Trial ParticipantsKathrine Meyers, Kristina Rodriguez, Atrina L Brill, et al.HIV Clinical Trials|November 18, 2018
Satisfaction and acceptability of cabotegravir long-acting injectable suspension for prevention of HIV: Patient perspectives from the ECLAIR trialMiranda I Murray, Martin Markowitz, Ian Frank, et al.Pageof 16